Loading…

Bio-TechneTECHCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Makes research reagents, proteins, antibodies and diagnostic tools used by biotech, pharma and academic labs for life-sciences research.

Momentum leader 88
Mkt cap
$11.4B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$227M
20-day average traded
Fwd P/E
34.4×
forward earnings
ROIC−WACC
-1.5 pp
WACC 11.4%
Hurdle
+26 pp
Req g minus delivered
Next earnings
76 days
2 Feb 2027
Close · USD$72.75
1D+0.2%
1W-0.1%
1M+0.2%
3M+0.7%
6M+55.8%
YTD+24.1%
1Y+24.5%
ATR %0.2%
Beta0.61
52w lowhigh0.2% off high

What Bio-Techne does

Makes research reagents, proteins, antibodies and diagnostic tools used by biotech, pharma and academic labs for life-sciences research.

Most sales are small repeat orders for catalog proteins and antibodies, which labs reorder as they run experiments; instruments such as automated protein analyzers then pull through reagent sales. Diagnostics and spatial-biology tests, built up through acquisitions such as Advanced Cell Diagnostics in 2017, are the other main line.

Products and services

  • Proteins/antibodies/reagents
  • Diagnostics (Exosome Dx, ACD spatial biology)
  • Cell and gene therapy tools

Customers

  • Biotech and pharma R&D labs
  • Academic/clinical research institutions

Where it sits in the supply chain

  • Healthcare/life sciences tools
  • Research reagents and diagnostics
  • Protein/antibody manufacturing and…

What could go right

  • Spatial biology/proteomics research growth
  • Cell and gene therapy tools demand

What could go wrong

  • Biotech/academic R&D funding cyclicality
  • Reagent pricing competition

Moat: narrow (brand, scale, distribution). A broad catalog and established brand recognition (R&D Systems) among life-sciences researchers support recurring sales.

Headquarters: Minneapolis, Minnesota, US · Founded: 1976 · Employees: 3,000

Named competitors

Bio-Techne at a glance

Size Bio-Techne (TECH) is a United States Health Care company (Biotechnology) with a market value of $11.4B, the 714th largest of 3,085 United States companies the cockpit tracks. Shares closed at $72.75 on 18 Nov 2026.

Performance Over six months the shares gained 55.8%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 0.9% over the last twelve months (peer median +32.0%); the operating margin is 21.3% (peer median 8.5%).

Valuation It trades at 34.4× forward earnings against a peer median of 28.5× (6th cheapest of 11).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.5 points below its cost of capital (11.4% WACC).

Short interest Short interest is 4.9% of the free float (30 Oct 2026).

Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026TECH 154Peer median 119
Six months, rebased to 100: Bio-Techne against the median of its 20 peers (local-currency closes).

Bio-Techne financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$1.23B$1.22B$1.22B$1.16B$1.14B
Revenue growth—0%+5%+2%—
Gross profit$810M$779M$779M$773M$770M
EBITDA$359M$373M$363M$387M$388M
Net income$172M$182M$73.4M$168M$285M
Free cash flow$308M$263M$257M$236M$216M
Capital expenditure$29.4M$28.9M$31.0M$62.9M$38.2M
Total debt$286M$289M$444M$420M$455M

Quarterly statements and history in the cockpit →

Bio-Techne competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%BMRN1093HALOKYMR002422ELANKRYSPCVX1961701548BBIOSMMTTWSTNBIXTXGCGONAXSMIMVTKODBNTXTECH6-month return →1-month return →
Up and to the right = strong over both horizons. Bio-Techne is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×BMRN1093HALO002422ELANKRYS1961701548NBIXAXSMTECHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bio-Techne is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%BMRN1093HALO002422ELANKRYS1961701548NBIXTXGTECHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bio-Techne is the large dot.

Bio-Techne competitors and peer comparison

Head to head with its named competitors (TECH vs TMO vs DHR vs SRT.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bio-Techne TECH$11.4B+56%+1%21%34.4×31.6%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Sartorius SRT.DE$19.9B+26%+4%18%43.0×25.6%
Bio-Rad Laboratories BIO$10.1B+29%+1%9%34.6×26.0%

How Bio-Techne compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bio-Techne against its 20 peers (data as of 18 Nov 2026)
MeasureTECHPeer medianRank in peer set
1-month return+0.2%-5.4%9th highest of 21
6-month return+55.8%+23.0%5th highest of 21
Distance from 52-week high-0.2%-26.2%highest of 21
Revenue growth (TTM)+0.9%+32.0%4th lowest of 17
Operating margin21.3%8.5%6th highest of 17
Forward P/E34.4×28.5×6th cheapest of 11
Growth the price implies (Req g, 7 yrs)31.6%10.7%4th most demanding of 11
Growth delivered (Del g)+5.5%+18.2%3rd lowest of 11
Hurdle (Req g minus delivered)+26.2 pp-7.3 pp2nd most demanding of 11
ROIC minus cost of capital-1.5 pp-5.7 pp8th highest of 16
EV / EBITDA31.7×16.0×4th most expensive of 9
Net debt / EBITDA-0.2×-1.1×4th most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a

Questions

Who are Bio-Techne's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Danaher (Cytiva) (DHR), Sartorius (SRT.DE), Bio-Rad Laboratories (BIO). The cockpit's measured peer set (industry) also includes BioMarin Pharmaceutical (BMRN), Cspc Pharma (1093.HK), Halozyme Therapeutics (HALO), Kymera Therapeutics (KYMR), Sichuan Kelun Pharmaceutical (002422.SZ), Elanco Animal Health (ELAN).
Is Bio-Techne expensive compared with its peers?
On forward p/e it trades at 34.4× against a peer median of 28.5×, 6th cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Bio-Techne stock performed?
Over six months to 18 Nov 2026 the shares returned +55.8% against +23.0% for the median peer; over one year +24.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.